Drug Trial Radar · NCT03114319
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
227
Actual
Start
May 26, 2017
Primary completion
Jul 4, 2025
Study completion Jul 4, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.
Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)
- KRAS G12-mutant NSCLC
- Esophageal Squamous Cell Cancer (SCC)
- Head/Neck SCC
- Melanoma
- Advanced Gastrointestinal Stromal Tumors (GIST)
- Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions
TNO155Drug
TNO155 for oral administration
TNO155 in combination with EGF816 (nazartinib)Drug
TNO155 for oral administration; EGF816 (nazartinib) for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events and serious adverse eventsTime frame: up to 5 years; at least once per treatment cycle
- Number of participants with dose limiting toxicitiesTime frame: up to 28-day cycle
- Number of participants with dose interruptions and reductionsTime frame: Up to 5 years
- Dose intensity of study drugsTime frame: Up to 5 years
Locations
18 sites in 9 countries. Site status is shown where the registry gives one.
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Dana Farber Cancer Center
Boston, Massachusetts
Memorial Sloane Ketterin Cancer Ctr
New York, New York
Sarah Cannon Research Institute
Nashville, Tennessee
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Kobe, Japan
Novartis Investigative Site
Amsterdam, Netherlands
Novartis Investigative Site
Rotterdam, South Holland, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.